AI drug discovery startup Isomorphic Labs enters fundraising talks with a valuation of at least $40 billion

On October 8, Isomorphic Labs, the AI drug discovery company led by Demis Hassabis under Alphabet, is in early-stage negotiations for a new round of financing, with a valuation of at least $40 billion, potentially reaching $50 billion. The company completed a $2.1 billion Series B funding round in May this year. The report also notes that the application of AI in the biopharmaceutical sector remains in its early stages, requiring further efforts to reach clinical trials and product launch. The negotiations are still in their early stages, and specific terms and investor details have not been disclosed.